{"nctId":"NCT03976102","briefTitle":"Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma","startDateStruct":{"date":"2019-05-15","type":"ACTUAL"},"conditions":["Follicular Lymphoma"],"count":317,"armGroups":[{"label":"Arm A: DRL_RI","type":"EXPERIMENTAL","interventionNames":["Biological: DRL_RI (Proposed rituximab biosimilar)"]},{"label":"Arm B: MabThera®","type":"ACTIVE_COMPARATOR","interventionNames":["Other: MabThera®"]}],"interventions":[{"name":"DRL_RI (Proposed rituximab biosimilar)","otherNames":[]},{"name":"MabThera®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject is Male or female subjects aged ≥18 years of age.\n2. Subject is histologically confirmed, Grade 1-3a, previous ly untreated, CD20-pos itive.\n3. Subject has Ann Arbor Stage II to IV and ECOG status of 0 to 1.\n4. Subject has Low tumor burden follicular lymphoma as per Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria\n5. Subject has at least 1 measurable tumor mass in 2 dimensions, and the mass must be:\n\n   1. Nodal lesion \\>15 mm in the longest dimension; or\n   2. Noda l lesion \\>10 mm to he longest dimension; dimens ion and \\>10 mm in the shortest dimension; or\n   3. Extra-nodal lesion with both long and short dimensions ≥10 mm.\n6. Subject has Life expectancy ≥3 months.\n7. If female subject, then subject should be non-pregnant, non-lactating.\n\nExclusion Criteria:\n\n1. Subject with prior use of rituximab or any CD20 monoclonal antibody for any reason.\n2. Subjects with known hypersensitivity to rituximab or its excipients, or to proteins of murine or other foreign origin.\n3. Any prior therapy for follicular lymphoma (including but not limited to chemotherapy, radiotherapy) or subjects on chronic supra-substitutive doses of systemic gluco-corticosteriods.\n4. Subjects who, in the opinion of the Investigator, require additional concomitant treatment for lymphoma.\n5. Evidence of histologic transformation to high grade lymphoma or diffuse large B-cell lymphoma.\n6. Subjects with known sero-positivity for or history of active viral infection with human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) will be excluded. And if positive for hepatitis B core antibody or hepatitis C virus (HCV) antibody can only be enrolled if HBV - DNA level \\<20 IU/mL (or 112 copies/mL) and HCV - RNA is negative respectively by PCR test..\n7. Subjects who have received a live vaccine within last 3 months of the first administration of study drug.\n8. Subjects with history or presence of a medical condition or disease that in the Investigator's opinion would place the subject at an unacceptable risk for study participation.\n9. Participation in any clinical study or having taken any investigational therapy (within 2-months of the first dose of study drug.\n10. Women of childbearing potential who do not consent to use highly effective methods of birth control.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Best Overall Response Rate (BORR) for Low Tumor Burden Follicular Lymphoma","description":"Best Overall Response Rate (BORR) is defined as the proportion of participants in each treatment group that achieved a best overall response of either Complete response (CR), unconfirmed Complete response (CRu) or Partial response (PR), up to Month 7 (Week 28) based on central radiology review in accordance with the Cheson, 1999 response criteria for Non-Hodgkin's Lymphomas. As per Cheson 1999, response criteria for target lesions and assessed by radiology: Complete response (CR): All lesions with a longest diameter should be regressed to normal size (≤ 15 mm) or short axis regressed to ≤ 10 mm with confirmed Bone marrow normalization; unconfirmed Complete response (CRu): All lesions with a longest diameter should be regressed to normal size (≤ 15 mm) or short axis regressed to ≤ 10 mm with non-confirmed Bone marrow normalization; Partial Response (PR): ≥ 50 % decrease of sum of products of diameter(SPD) of all the target lesions; Overall Response (OR)=CR+CRu+PR.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.2","spread":null},{"groupId":"OG001","value":"79.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR)","description":"The overall response rate (ORR) is defined as proportion of participants in each treatment group achieved a complete response or partial response at week 12 and week 28 based on central radiology review in accordance with published response criteria for malignant lymphoma. As per Cheson 1999, response criteria for target lesions and assessed by radiology: Complete response (CR): All lesions with a longest diameter should be regressed to normal size (≤ 15 mm) or short axis regressed to ≤ 10 mm with confirmed Bone marrow normalization; unconfirmed Complete response (uCR): All lesions with a longest diameter should be regressed to normal size (≤ 15 mm) or short axis regressed to ≤ 10 mm with non-confirmed Bone marrow normalization; Partial Response (PR): ≥ 50 % decrease of sum of products of diameter(SPD) of all the target lesions; Overall Response (OR)=CR+uCR+PR.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","spread":null},{"groupId":"OG001","value":"63.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.3","spread":null},{"groupId":"OG001","value":"73.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response Rate","description":"Complete Response rate is defined as the proportion of participants in each treatment group who achieved complete response up to particular visit based on investigator assessment in accordance with the response criteria for malignant lymphoma. As per Cheson 1999, response criteria for target lesions and assessed by radiology: Complete response (CR): All lesions with a longest diameter should be regressed to normal size (≤ 15 mm) or short axis regressed to ≤ 10 mm with confirmed Bone marrow normalization.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","spread":null},{"groupId":"OG001","value":"34.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response Rate as a Best Response","description":"Complete Response Rate as a Best Response is defined as the proportion of participants in each treatment group that achieved the best complete response up to Week 28 based on central radiology review in accordance with the Cheson 1999, response criteria for malignant lymphoma. As per Cheson 1999, response criteria for target lesions and assessed by radiology: Complete response (CR): All lesions with a longest diameter should be regressed to normal size (≤ 15 mm) or short axis regressed to ≤ 10 mm with confirmed Bone marrow normalization.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.0","spread":null},{"groupId":"OG001","value":"35.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR)","description":"Duration of response (DOR) defined as the time from date of the first documentation of tumor response (Complete Response, unconfirmed complete response or partial response) to the date of first documentation of progressive disease (PD) or to death due to any cause up to 52 weeks/ End of study (EOS). Progression is defined as per Cheson 1999, response criteria is:\n\nTarget Nodal SPD Progression: at least one node must be abnormal, and the SPD of all nodes must increase by ≥ 50% from its nadir SPD.\n\nTarget Extranodal SPD Progression: at least one extranodal lesion must be present and the SPD of all extranodal lesions must increase by ≥ 50% from its nadir SPD.\n\nAlso, if a patient had any unequivocal progression in non-target lesions; and detection of any new nodal lesion (longest diameter \\[LDi\\] 15mm with an absolute increase of 5mm) his/her response was considered as Progressive disease.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"Progression-free survival (PFS) is defined as the time from date of randomization to the date of documented progressive disease or death due to any cause. Progression is defined as per Cheson 1999, response criteria is:\n\nTarget Nodal SPD Progression: at least one node must be abnormal, and the SPD of all nodes must increase by ≥ 50% from its nadir SPD.\n\nTarget Extranodal SPD Progression: at least one extranodal lesion must be present and the SPD of all extranodal lesions must increase by ≥ 50% from its nadir SPD.\n\nAlso, if a patient had any unequivocal progression in non-target lesions; and detection of any new nodal lesion (LDi 15mm with an absolute increase of 5mm) his/her response was considered as Progressive disease.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"The Overall survival (OS) defined as the time from date of randomization to the date of death from any cause up to 52 weeks or EOS.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"The safety and tolerability of DRL\\_RI and MabThera® in participants with CD20-positive, LTB-FL was evaluated.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Positive Anti-drug Antibody (ADA)","description":"The immunogenicity of the Proposed Rituximab Biosimilar (DRL\\_RI) with MabThera® among trial participants was compared.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":162},"commonTop":["COVID-19","Pruritus","Nausea","Neutropenia","Abdominal pain"]}}}